Thursday, 15 October 2026European Markets

CABKA Stock Over 28% Up In The Last 21 Sessions

Loading stream...

(VIANEWS) - Shares of CABKA (AEX-Index: CABKA.AS) rose by a staggering 28.52% in 21 sessions from €6.1 to €7.84 at 11:07 EST on Thursday, following the last session's upward trend. AEX-Index is dropping 0.48% to €771.28, after two successive sessions in a row of gains.

CABKA's last close was €7.80, 2.74% under its 52-week high of €8.02.

About CABKA

Cabka N.V. manufactures and sells pallets and containers made from recycled plastic in Europe and North America. The company sells its recycled plastic products to blue chip clients in the food and beverage, retail, automotive, dairy, meat and poultry, chemical, pharmaceutical, and pooling industries in approximately 80 countries. Cabka N.V. was incorporated in 1994 and is headquartered in Berlin, Germany.

Earnings Per Share

As for profitability, CABKA has a trailing twelve months EPS of €-1.27.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -56.08%.

Sales Growth

CABKA's sales growth for the current quarter is 10.2%.

Volatility

CABKA's last week, last month's, and last quarter's current intraday variation average was a negative 0.51%, a positive 1.09%, and a positive 2.30%.

CABKA's highest amplitude of average volatility was 1.38% (last week), 2.88% (last month), and 2.30% (last quarter).

Yearly Top and Bottom Value

CABKA's stock is valued at €7.84 at 11:07 EST, under its 52-week high of €8.02 and way above its 52-week low of €5.50.

More news about CABKA (CABKA.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com